drugset
drugset / Trial / NCT05930704

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

NCT05930704 ↗

Phase 1 Unknown 45 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single subcutaneous (SC) injection in postmenopausal women

Timeline

Start
2023-07-04
Primary completion
2025-04-12
Completion
2025-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-2017 Unknown — Subcutaneous

Indications

osteoporosis